Mackenzie Financial Corp Buys 460,501 Shares of Accuray Incorporated (NASDAQ:ARAY)

Mackenzie Financial Corp raised its stake in shares of Accuray Incorporated (NASDAQ:ARAY) by 168.8% in the 1st quarter, HoldingsChannel.com reports. The firm owned 733,347 shares of the medical equipment provider’s stock after purchasing an additional 460,501 shares during the period. Mackenzie Financial Corp’s holdings in Accuray were worth $1,313,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently made changes to their positions in the business. Gabelli Funds LLC boosted its stake in shares of Accuray by 12.5% in the fourth quarter. Gabelli Funds LLC now owns 45,000 shares of the medical equipment provider’s stock worth $89,000 after acquiring an additional 5,000 shares during the period. Geode Capital Management LLC boosted its stake in shares of Accuray by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 2,186,154 shares of the medical equipment provider’s stock worth $4,329,000 after acquiring an additional 6,758 shares during the period. Northern Trust Corp boosted its stake in shares of Accuray by 0.9% in the fourth quarter. Northern Trust Corp now owns 809,665 shares of the medical equipment provider’s stock worth $1,603,000 after acquiring an additional 7,399 shares during the period. ProShare Advisors LLC boosted its stake in shares of Accuray by 50.7% in the fourth quarter. ProShare Advisors LLC now owns 27,308 shares of the medical equipment provider’s stock worth $54,000 after acquiring an additional 9,187 shares during the period. Finally, North Star Investment Management Corp. boosted its stake in shares of Accuray by 1.0% in the first quarter. North Star Investment Management Corp. now owns 1,058,545 shares of the medical equipment provider’s stock worth $1,895,000 after acquiring an additional 10,000 shares during the period. Institutional investors own 64.08% of the company’s stock.

Accuray Price Performance

NASDAQ:ARAY opened at $1.29 on Tuesday. The company has a current ratio of 1.64, a quick ratio of 0.92 and a debt-to-equity ratio of 3.35. Accuray Incorporated has a 12 month low of $1.14 and a 12 month high of $2.95. The business’s 50-day moving average is $1.37 and its 200 day moving average is $1.67.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Accuray from a “hold” rating to a “buy” rating in a research note on Friday, May 30th.

Accuray Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.